Original from: 360dx

Cardiovascular testing firm Prevencio and Quadrant Health said Thursday that they have entered an agreement to integrate Prevencio's HART CVE and HART CADhs blood tests into Quadrant's primary care workflows to better translate the test results into clinical action and measure outcomes.

Financial and other terms of the deal were not disclosed.

Kirkland, Washington-based Prevencio combines protein biomarker measurements with AI analyses for cardiovascular testing. The company's HART CVE test is meant to determine an individual's one-year risk of heart attack, stroke, or cardiac death in order to risk stratify patients with chronic total occlusions for major cardiac adverse events (MACE) and cardiovascular death. Its CADhs test is meant to diagnose obstructive coronary artery disease and identify individuals at imminent risk of a heart attack.

Beverly, Massachusetts-based Quadrant Health provides AI tools for improving the efficiency of clinical workflows.

The partners said they will initially focus on primary care populations, where earlier identification and clearer stratification of cardiometabolic risk can support more personalized prevention strategies and care planning.

“By integrating HART CVE and HART CADhs blood tests into primary care workflows, we are helping clinicians move from uncertainty to clarity — so they can intervene earlier, personalize next steps, and keep patients on the right care path," Rhonda Rhyne, CEO and Chief Translational Officer of Prevencio, said in a statement.

"This partnership advances our commitment to proactive, patient-centered care," Quadrant CEO Anin Sayana said in a statement. "Bringing advanced AI-based cardiac risk insights into primary care supports more timely decisions, better care navigation, and a more seamless experience for patients."

Source: Prevencio, Quadrant Health Partnering on Cardiovascular Testing